In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
Many patients seek Chinese herbal medicines (CHM) from traditional Chinese medicine (TCM) clinics. This study aimed to estimate the risk of major adverse cardiovascular events (MACEs) in adults ...
BREAKING: One of the Season 7 Love Is Blind Washington, D.C contestants works for a radical dark money group collaborating with the Chinese Communist Party to ban gas stoves. https://t.co/H6Bs0dPcYX ...